Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Editor-in-Chief: David D. Ho, MD
Paul A. Volberding, MD
William A. Blattner, MD
ISSN: 1525-4135
Online ISSN: 1077-9450
Frequency: 15 issues per year
Ranking: Infectious Diseases 9/57
Immunology 26/128
Impact Factor: 4.57

July 2010 Supplement, Volume 54, Supplement 1
Inclusion of Adolescents and Young Adults in Biomedical HIV Prevention Research

Guest Editors: Bill G. Kapogiannis, M.D., Monica S. Ruiz, Ph.D., MPH, Ed Handelsman, M.D. and Sonia Lee, Ph.D.

Current Supplement

 

Journal Announcement

Journal Announcement

New Focus Area: Implementation and Operational Research

JAIDS is now accepting manuscripts for a new focus area of interest: Implementation and Operational Research.   As highlighted by NIH Director, Dr. Francis Collins “Implementation science is part of [the NIH research] mission.”

In the context of HIV/AIDS with advances in HIV therapy and care, expansion of global access to treatment, care and prevention Implementation and Operational Research, while having particular relevance to global health is an important domestic focus as well.   However the lessons learned through this research discipline are particularly relevant to guiding best practices in low-resource settings as antiretroviral drug access is expanded.  Articles that encompass the translation of knowledge, practices, and technologies into clinical care of adult and pediatric patients with HIV/AIDS and their evidence-based effectiveness in “real world settings” are of particular interest. 

View the latest Instructions to Authors.

Current Issue Highlights

Select All | Hide Details
Select All
NEW! Articles on your eReader
Login




Help

Forgot Password?

Need to Activate a New Subscription?
Recently purchased a subscription? Login or Register a new account and enter your subscription ID, or Subscribe Now!

Editors' Picks

As clinical trials are increasingly conducted globally, this report adds appropriate caution that local and regional population differences and co-morbidities must always be kept in mind.  While serum chemistries were comparable between US-based toxicity tables, many healthy African children would have been scored as anemic using US standards.

This article reports the extended efficacy and safety results of the integrase inhibitor, raltegravir, in treatment naïve adults. While not materially different than the preliminary 48 week results previously published, this is an extremely important new drug and these results confirm the excellent potency combined with reassuring safety that make the drug such an attractive agent.

As PEPFAR and Global Fund continue to expand treatment access to millions infected with HIV in Africa and around the world, this analysis tells a cautionary tale about the emerging threat of drug resistance.  Expanded treatment access is not a simple public health activity but requires the application of both sophisticated medical knowledge and public health principle to ensure that the maximum number benefit from therapy while promoting best adherence to therapy and prevention for positives safe sex practices.

Other Ways to Connect
Recognition of our Reviewers